Abstract:Tumor metastasis has become a fatal disease progress which greatly influence cancer treatment and prognosis. Generally, the metastatic progression can be classified into three main processes: the cancer cells leave the original “tumor home”, travel through “vessel highway”, and settle down in a new “tissue house”. Many agents with various machnisms have been developed for the treatment of cancer cell metastasis, including VEGFR inhibitors, integrin inhibitors, or MMP (matrix metallo protease) inhibitors. Recently a growing interest has been shown for the CXC chemokine receptor 2 (CXCR2), due to their involvement in metastasis physiology. Once CXCR2 is triggered by upstream effectors, it can cause the activation of downstream signals such as serine/threonine kinases, tyrosine kinases. Its essential role in influencing tumor microenvironment makes CXCR2 an important target for anti-tumor metastasis treatment. The first non-peptide CXCR2 antagonist SB225002 was discovered in the mid-1990s by GSK Company. To date, four drug candidates are in clinical trials, including Danirixin, AZD5069, Reparixin and Ladarixin. The clinical indications of AZD5069 were expanded to metastatic head & neck cancer and metastatic pancreatic cancer, in combination with MEDI4736 (a PDL-1 inhibitor). As an excellent computational tool, the pharmacophore model, has been rapidly developed for the identification of novel hit/lead compounds for various targets, especially for proteins without crystal structures. An extensive effort has been made in the attempt to apply pharmacophore model to identify novel VEGFR inhibitors, MMP inhibitors as anti-cancer metastasis agents, revealing that ligand-based pharmacophore model is the best approach when the target geometry is not available, or the binding mode is not elucidated. At present, the binding mode of CXCR2 with its antagonists has not been fully discovered, however, the group of N. Neamati have been trying to establishing a ligand-based pharmacophore model which could be applied for virtual screening to find novel scaffolds of CXCR2 antagonist; this work, for the first time, indicated the feasibility of applying pharmacophore model for the discovery of CXCR2 antagonist. Although a bunch of CXCR2 antagonists have been identified, the anti-tumor metastasis effect of CXCR2 antagonists is not considered in most cases. In our study, a convenient pharmacophore model was built with HipHop program, by screening a mini-database contained compounds which were designed based on the known structure-activity relationship (SAR) of the diarylurea series CXCR2 antagonists. Several novel skeletons with moderate to potent CXCR2 antigonitic activiites were identified. Following optimization resulted in the discovery of compound D45 which showed not only potent CXCR2 antagonist activity with an IC50 value of 10 nM and 910-fold selectivity against CXCR1, but also good in vitro anti-tumor metastatic effect in wound healing assay. Moreover, compound D45 exhibitored promising druglikeness with more than 90% bioavailability in rat. Citation Format: Wen-Hai Huang, Zhi-Long Wang, Jin-Xin Che, Hai-Chao Sheng, Feng Huang, Yong-Zhou Hu, You-Hong Hu, Xin Xie, Xiao-Wu Dong. The discovery of novel small molecular CXCR2 antagonist by using ligand-based pharmacophore model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-064.

TRAF6 Inhibitors from Marine Compound Library: Pharmacophore, Virtual Screening, Fragment Replacement, ADMET, and Molecular Dynamics

In Silico Investigation of Potential TRAF6 Inhibitor from Traditional Chinese Medicine Against Cancers.

Exploring marine-derived compounds for MET signalling pathway inhibition in cancer: integrating virtual screening, ADME profiling and molecular dynamics investigations

Targeting Yap/Taz-Tead Protein-Protein Interactions Using Fragment-Based And Computational Modeling Approaches

Molecular Docking‐based Virtual Screening and Dynamics Simulation Study of Novel and Potential SIRT7 Inhibitors

The Inhibitors of CDK4/6 from a Library of Marine Compound Database: A Pharmacophore, ADMET, Molecular Docking and Molecular Dynamics Study

Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma

Abstract LB-064: The discovery of novel small molecular CXCR2 antagonist by using ligand-based pharmacophore model

Leveraging the Fragment Molecular Orbital and MM-GBSA Methods in Virtual Screening for the Discovery of Novel Non-Covalent Inhibitors Targeting the TEAD Lipid Binding Pocket

Design of New Second‐Generation TRK Inhibitors Targeting Tropomyosin Receptor Kinases by Using Molecular Docking, Molecular Dynamics Simulations and ADMET Properties

Marine-derived EGFR Inhibitors: Novel Compounds Targeting Breast Cancer Growth and Drug Resistance

Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations

Identification of Novel P2X7R Antagonists by Using Structure‐based Virtual Screening and Cell‐based Assays

Design and screening of FAK, CDK 4/6 dual inhibitors by pharmacophore model, molecular docking, and molecular dynamics simulation

Design of novel anti-cancer drugs targeting TRKs inhibitors based 3D QSAR, molecular docking and molecular dynamics simulation

In Silico Study to Identify Novel NEK7 Inhibitors from Natural Sources by a Combination Strategy.

Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6 H-pyrimido[5,4- b][1,4]oxazin-7(8 H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants

Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study

In silico study to identify novel NEK7 inhibitors from natural source by a combination strategy

In Silico Screening of 1,3,4-Thiadiazole Derivatives as Inhibitors of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2)

Comparative profiling of analog targets: a case study on resveratrol for mouse melanoma metastasis suppression.